<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053764</url>
  </required_header>
  <id_info>
    <org_study_id>CSEG101A2203</org_study_id>
    <secondary_id>2018-003608-38</secondary_id>
    <nct_id>NCT04053764</nct_id>
  </id_info>
  <brief_title>Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease</brief_title>
  <acronym>STEADFAST</acronym>
  <official_title>A Phase II, Multicenter, Randomized, Open Label Two Arm Study Comparing the Effect of Crizanlizumab + Standard of Care to Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to compare the efficacy and safety of crizanlizumab + standard of&#xD;
      care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years&#xD;
      with chronic kidney disease due to sickle cell nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">January 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 9, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with ≥ 30% decrease in albuminuria (ACR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Proportion of patients with ≥ 30% decrease in ACR at 12 months compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in albuminuria (ACR)</measure>
    <time_frame>Baseline to 3, 6, 9, and 12 months</time_frame>
    <description>Mean change in ACR from baseline to 3, 6, 9, and 12 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥ 30% decrease in albuminuria (ACR)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Proportion of patients with ≥ 30% decrease in ACR at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥ 20% improvement of protein to creatinine ratio (PCR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Proportion of patients with PCR improvement at 12 months compared to baseline. Improvement: ≥ 20% decrease in PCR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a stable (within ± 20% change) protein to creatinine ratio (PCR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Proportion of patients with stable PCR at 12 months compared to baseline. Stable: within ± 20% change in PCR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Baseline to 3, 6, 9, and 12 months</time_frame>
    <description>Percentage change in eGFR from baseline to 3, 6, 9, and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of albumin to creatinine ratio (ACR) decline</measure>
    <time_frame>Baseline to 3, 6, 9, and 12 months</time_frame>
    <description>Slope of ACR decline from baseline to 12 months of treatment based on ACR values at baseline and at 3, 6, 9, and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of estimated glomerular filtration rate (eGFR) decline</measure>
    <time_frame>Baseline to 3, 6, 9, and 12 months</time_frame>
    <description>Slope of eGFR decline from baseline to 12 months of treatment based on eGFR values at baseline and at 3, 6, 9, and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with progression of chronic kidney disease (CKD)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Proportion of patients with progression of CKD from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab.</measure>
    <time_frame>Baseline to follow-up period, at select time points approx. 1 year and 4 months</time_frame>
    <description>Measurement of ADA to crizanlizumab at select time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of visits to emergency room (ER) and hospitalizations</measure>
    <time_frame>Baseline to follow-up period, approx. 1 year and 4 months</time_frame>
    <description>Annualized rate of visits to ER and hospitalizations due to Acute Kidney Injury (AKI) events, Vaso-occlusive crisis (VOCs), or other Sickle Cell Disease (SCD) complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentration (Ctrough) of crizanlizumab</measure>
    <time_frame>Baseline to follow-up period, at select time points approx. 1 year and 4 months</time_frame>
    <description>Crizanlizumab pre-dose/trough pharmacokinetic samples will be taken at select time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Sickle Cell Disease (SCD)</condition>
  <arm_group>
    <arm_group_label>crizanlizumab + standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizanlizuamb</intervention_name>
    <description>Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab</description>
    <arm_group_label>crizanlizumab + standard of care</arm_group_label>
    <other_name>SEG101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)</description>
    <arm_group_label>crizanlizumab + standard of care</arm_group_label>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of SCD (HbSS and HbSβ0-thal SCD genotypes are eligible)&#xD;
&#xD;
          -  Patients with eGFR ≥ 45 to ≤ 140 mL/min/1.73 m2 based on CKD EPI formula (patients ≥&#xD;
             18) or the Creatinine-based &quot;Bedside Schwartz&quot; equation (patients &lt; 18)&#xD;
&#xD;
          -  Patients with ACR of ≥ 100 to &lt; 2000 mg/g (taken as an average of the three screening&#xD;
             ACR values to determine eligibility)&#xD;
&#xD;
          -  Receiving at least 1 standard of care drug(s) for SCD-related CKD: If receiving HU/HC,&#xD;
             the patient must have been receiving HU/HC for at least 6 months and on a stable dose&#xD;
             for 3 months, and/or an ACE inhibitor and/or ARB for 3 months and on a stable dose for&#xD;
             those 3 months.&#xD;
&#xD;
          -  Hb ≥ 4.0 g/dL, absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L, and platelet count ≥ 75&#xD;
             x 10^9/L&#xD;
&#xD;
          -  Adequate hepatic function as defined by:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &lt; 3.0 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Direct (conjugated) bilirubin ≤ 3.0 x ULN&#xD;
&#xD;
          -  Written informed consent (or assent/ parental consent for minor subjects) prior to any&#xD;
             screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of stem cell transplant&#xD;
&#xD;
          -  Patients with evidence of AKI within 3 months of study entry (can decrease interval to&#xD;
             within 6 weeks of study entry only if renal function has returned to pre-AKI values&#xD;
             prior to study entry)&#xD;
&#xD;
          -  Blood pressure &gt; 140/90 mmHg despite treatment&#xD;
&#xD;
          -  Patients undergoing renal replacement therapy (ie. hemodialysis, peritoneal dialysis,&#xD;
             hemofiltration and kidney transplantation)&#xD;
&#xD;
          -  Received blood products within 30 days of Week 1 Day 1&#xD;
&#xD;
          -  Participating in a chronic transfusion program&#xD;
&#xD;
          -  History of kidney transplant&#xD;
&#xD;
          -  Patients with hypoalbuminemia&#xD;
&#xD;
          -  Body mass index of ≥ 35&#xD;
&#xD;
          -  Currently receiving or received voxelotor within 6 months of screening&#xD;
&#xD;
          -  Patient has received crizanlizumab and/or other selectin inhibitor or plans to receive&#xD;
             it during the duration of the study.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicky Staton</last_name>
      <phone>843-792-1815</phone>
      <email>nsharris@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Kanter-Washko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-265-8199</phone>
    </contact>
    <investigator>
      <last_name>Molly Weidner Mandernach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eldrida Randall</last_name>
      <phone>404-778-1480</phone>
      <email>ecart05@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Fuad El-Rassi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois Hospital and Health Sciences System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Taif</last_name>
      <email>tohassan@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Santosh Saraf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Doyle</last_name>
      <phone>225-214-3638</phone>
      <email>Julie.Doyle@fmolhs.org</email>
    </contact>
    <investigator>
      <last_name>Vince Cataldo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LSU Medical Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet Johnson</last_name>
      <phone>318-675-5661</phone>
      <email>hjohn3@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Mansour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Plazas Montana</last_name>
      <phone>+1 443 287 4532</phone>
      <email>mplazas2@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Sophie Lanzkron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University BrodySchool of Med. (3)</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>252-744-4773</phone>
    </contact>
    <investigator>
      <last_name>Darla Liles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Tenn Health Sciences Ctr</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula S McCune</last_name>
      <phone>901-448-2813</phone>
      <email>pmccune@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Ataga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Imongan</last_name>
      <phone>713-500-6852</phone>
      <email>Brenda.Imongan@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Modupe Idowu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20.211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01232-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Larisa</city>
        <zip>41221</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gela</city>
        <state>Sicily</state>
        <zip>93012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tripoli</city>
        <zip>1434</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <zip>0801</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Guateng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antakya / Hatay</city>
        <zip>31100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SEG101</keyword>
  <keyword>SCD</keyword>
  <keyword>Crizanlizumab</keyword>
  <keyword>Sickle cell nephropathy</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>albuminuria (ACR)</keyword>
  <keyword>renal function</keyword>
  <keyword>standard of care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

